Current Report Filing (8-k)
April 04 2022 - 12:29PM
Edgar (US Regulatory)
0000727346
false
0000727346
2022-03-30
2022-03-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 30, 2022
SELECTIS
HEALTH, INC.
(Exact Name of Registrant as Specified in its
Charter)
Utah
|
|
0-15415
|
|
87-0340206
|
(State
or other jurisdiction
of
incorporation) |
|
Commission
File
Number |
|
(I.R.S.
Employer
Identification
number) |
8480
E. Orchard Road, Ste. 4900, Greenwood Village, CO 80111
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (720) 680-0808
(Former
name or former address, if changed since last report)
☐ |
Written
communications pursuant to Rule 425 under the Securities Act |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each Class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
N/A |
|
N/A |
|
N/A |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
ITEM
3.02 UNREGISTERED SALE OF EQUITY SECURITIES
The
following sets forth the information required by Item 701 of Regulation S-B with respect to the unregistered sales of equity securities
by Selectis Health, Inc., a Utah corporation (the “Company”):
|
a. |
Effective
March 30, 2022, the Company granted to each Lance Baller, CEO of the Company and Randy Barker, President and COO of the Company,
a Non-Qualified Stock Option exercisable to purchase 100,000 shares of common stock of the Company at an exercise price of $7.00
per share (the “Option”). The Options have a cashless exercise provision, are fully vested as of March 30, 2022, and
are exercisable for a period of ten years. |
|
|
|
|
b. |
The
Company paid no fees or commissions in connection with the issuance of the Option. |
ITEM
5.02 COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS
Effective
March 30, 2022, Selectis Health, Inc., approved the grant of common stock options (“Options”) to certain of its officers.
Lance Baller, CEO, and Randy Barker, President and COO were each granted Non-Qualified Stock Options exercisable to purchase an aggregate
of 100,000 shares of common stock. The Options are fully vested upon grant. Copies of the Option Agreements are filed herewith as Exhibits
10.1 and 10.2 respectively.
ITEM
9.01: EXHIBITS
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
|
Selectis
Health, Inc. (Registrant) |
|
|
Dated:
April 4, 2022 |
/s/
Lance Baller |
|
Lance
Baller, CEO |
Selectis Health (PK) (USOTC:GBCS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Selectis Health (PK) (USOTC:GBCS)
Historical Stock Chart
From Jul 2023 to Jul 2024